Grants and Contributions:
Title:
Development of chemically modified bifunctional oligonucleotides for therapeutic protein upregulation
Agreement Number:
1041685
Agreement Value:
$75,000.00
Agreement Date:
Apr 1, 2026 - Nov 13, 2026
Description:
Orb will develop and apply translational assay capabilities in relevant cellular models to evaluate and prioritize RNA therapeutic candidates for selected disease programs. The resulting data package will support downstream preclinical planning, strategic partnership discussions, and financing activities.
Organization:
National Research Council Canada
Expected Results:
The expected results and outcomes of NRC Industrial Research Assistance Program is focused on growing small and medium-sized enterprises (SMEs) through innovation and wealth creation for Canada.
Location:
Toronto, Ontario, CA M5G 1M1
Reference Number:
172-2026-2027-Q1-1041685
Agreement Type:
Contribution
Report Type:
Grants and Contributions
Recipient Business Number:
709922819
Recipient Type:
For-profit organization
Recipient's Legal Name:
Orb Therapeutics Inc.
Federal Riding Name:
University--Rosedale
Federal Riding Number:
35110
Program:
Industrial Research Assistance Program
Program Purpose:
The purpose of Industrial Research Assistance Program Contributions to Firms is to provide support that assists small and medium-sized enterprises (SMEs) to advance their innovation knowledge and ability to innovate, grow through innovation and stimulate wealth creation for Canada.
Coverage:
Industrial Research Assistance Program projects stimulate wealth creation for Canada through technological innovation and strengthen Canadian innovation ecosystem by creating new industrial capacity.
NAICS Code:
541710